

Biocept got patent for its Molecular Biomarker Technology

08 January 2018 | News

Expands intellectual property position to 22 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)



Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.

The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer.

The company announced the issuance of Australian Patent No. 2012250516, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS.

This is the second issued patent for Biocept's Target Selector™ assays for molecular analysis using real-time PCR, Sanger sequencing and next generation sequencing (NGS).

Consistent with Biocept's recently issued U.S. patent, the Australian patent encompasses Biocept's proprietary "switch-blocker" technology,

It enhances the patient specimens for oncogene mutations of interest, resulting in ultra-high sensitivity and specificity for the detection of cancer associated mutations found in blood, tissue, and other biological sources.